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Abstract—Nowadays medical software is tightly coupled with
medical devices that perform patient state monitoring and lately
even some basic treatment procedures. Medical guidelines (GLs)
can be seen as specification of a medical system that includes
both software and electronic devices. However, often medical GLs
suffer from structural problems, such as incompleteness, inconsis-
tencies, ambiguity and redundancy. Formal representation of GLs
would enable the validation of GLs structural, real-time and life-
cycle properties. Several GLs formal representation methods have
been presented recently. Only some of them enable automatic
formal verification by introducing an additional translation path
to the existing model checking environments. However, if a
verified property fails it is difficult to trace back the result needed
to change the model. Moreover, these formalisms provide the
notion of time mostly in terms of actions order. In this paper
we preset a novel approach based on Timed Automata extended
with Tasks (TAT) for the medical protocol formal representation
using the TIMES toolbox. We discuss the verification issues with
the help of the Imatinib case study.
Index Terms—Medical Guidelines, Formalization, Timed Au-
tomaton, Verification.
I. INTRODUCTION
Recently, the set of electronic medical devices has a
tendency to be extended with a new class of closed-
loop/autonomous devices able to not only acquire the vital in-
formation but also perform some basic patient treatment [18].
Involvement of such devices in the health care process reduces
human factor errors, unfortunately, often with the price of
introduction of new errors due to failures or unpredictable
behaviors of the electronic systems. Medical Guidelines (GLs)
contain step-by-step recommendations for practitioners about
how to treat a patient. Therefore, they represent an informal
control flow that synchronizes the processes of data acquisi-
tion, decision-making and treatment provision and thus act as
an intersection point between medical software and electronic
devices, playing a role of a medical system specification.
Until now, most of the GLs are represented in a textual
format and therefore often suffer from such structural problems
as incompleteness, inconsistency, ambiguity and redundancy.
Therefore, it is essential to find a proper formal representation
for the GLs that would enable the validation of the GLs
structural and life-cycle properties. Several frameworks for the
computer-based interpretation of GLs have been presented in
the past three decades [11], [17], [24], [26], [27]. These tools
adapt flow-charts as a core formalism to represent a sequence
of actions. However, they enable validation of the protocol
structure only by means of their formal representation and have
no support for the automatic verification of the protocol formal
properties. Such frameworks as GLARE [25] and Asbru [14],
[21] provide translation links to model checking environments
such as SPIN [1] and SMV [2]. However, if a verified property
fails it is difficult to trace back the result needed to change
the initial protocol model. Moreover, these formalisms provide
the notion of time only in terms of actions order (in a flow-
chart). However, it is essential to map medical actions into the
time scale with respect to both medical software, when over-
time response definition to a treatment needs to be given, and
electronic device, when parts of the protocol are performed by
this device, and thus system real-time properties need to be
verified. We believe that cooperation of the two domains of
medical informatics and medical cyber-physical systems is an
important step in practitioners assistance that is aimed to help
them taking decisions and automate some routine actions thus
reducing the number of mistakes due to the human factor.
In this paper we show that a novel approach of [23] for the
medical GLs formal representation can bridge the gap between
medical software and electronic devices. The approach is
based on GLs formal representation with Timed Automaton
extended with Tasks (TAT) [7] and exploits the TIMES
toolbox [3] aimed to support the modeling and verification
of real-time systems. TIMES includes not only a Graphical
User Interface (GUI) for system modeling but also a model-
checker engine that supports system verification. Therefore, no
additional translation path and tracing back the result is needed
when performing the model verification. We present a case
study of modeling the Imatinib dose adjustment part of the
protocol for adult patients with newly diagnosed Philadelphia
positive (Ph+) Chronic Myeloid Leukemia (CML) comple-
mented. The model is complemented with the TAT-based
model of response definition to the treatment. We perform the
validation of the protocol structure as well as discuss issues
of the protocol real-time and life-cycle properties verification.
The paper is organized as follows. Section II gives an
overview of the existing formalisms. In Section III we define
the requirements to the modeling methodology and introduce
the TA and TAT models as our approach while showcasing
it with a small example. We also discusse the advantages
and disadvantages of TAT-based approach Section IV presents
the Imatinib case study and discusses the verification issues.
Section V concludes the paper.
II. RELATED WORK
In [18] authors present a formal approach to the develop-
ment of a Generic Patient Controlled Analgesic (GPCA) infu-
sion pump. Similar to our idea they approach the problem of
the safety-assured development of the pump software by using
TA model. The behavior is then verify with respect to a set
of generic safety requirements. After the verification process
they automatically generate a platform independent code using
the TIMES tool that is then adapted for a specific platform.
In this paper we use the TA modeling for a more general
purpose to formally represent the step by step procedures of
the medical treatment described in medical GLs. The GLs
can be viewed as a medical system behavior specification,
where actions are distributed between medical doctors, server
machines and embedded medical devices.
A number of specific languages and tools [4], [11], [12],
[14], [16], [17], [21], [22], [24]–[28] aimed to perform for-
malization of medical guidelines (GL) has been developed in
the past decades. PRODIGY [17] introduced in 1996 was the
first knowledge-based decision-support system. Its model is
organized as a network of patient scenarios, management de-
cisions and action steps which produce further scenarios called
a disease-state map. PRODIGY did not allow the description
of alternative scenarios or parallel actions. Its development
has been already discontinued, however, it has created a
fruitful base for other knowledge-based decision support tools.
EON [27] is a component-based suite for GL modeling and
creation of guideline-based applications. The EON architec-
ture is composed of Dharma and RESUME problem-solving
methods as well as a temporal query system called Chronus.
The Dharma model is divided into two parts the first of
which determines the eligibility of a patient for a treatment
procedure (diagnosis phase), while the second one, called
therapy planner, represents the treatment procedure. Similar to
PRODIGY, disease-state map approach of the therapy planner
is based on an abstract skeletal-plan. It is then gradually
refined using patient condition specific details provided by
RESUME that are then assigned to the skeletal plan elements
as attributes. The Guideline Interchange Format (GLIF) [11]
was developed to support guideline modeling as a flow-
chart. However, GLIF2 flowcharts attributes were represented
in plain text which introduces a problem in translation of
GLIF models into computable formalisms. The current version
of GLIF (GLIF3) is similar to GLIF2, however, a formal
structure for the class attributes is also provided. GUIDE [12]
is focused on providing an integrated medical knowledge
management through a unique central system and is composed
of three independent modules: Guideline Management Sys-
tem (GlMS) (providing clinical decision support), Electronic
Patient Record (EPR) and Workflow Management System
(WfMS) or Careflow Management System (CfMS) (providing
organizational support). The GUIDE graphical editor is a part
of the whole environment used to formally represent a general
GL as flow-charts that involve medical terms and concepts.
This GL can then be instantiated by an end user for the
management of an individual patient by annotating it with
patient data. From the point of view of the GL representation
GUIDE is similar to EON and GLIF by exploiting flow-charts
to represent the sequence of actions. However, it is more
focused on data centralization and distribution and thus goes
further with formalizing the data structure, using GEM [22],
and data access representation. In our work we are more
interested in the part of the protocol modeling equivalent to the
therapy planner of EON. Non of the mentioned above tools
support GLs formal verification.
Similar to other formalisms, GLARE [25] separates the
concerns of the protocol representation (acquisition) and their
execution or its application to a specific patient. The repre-
sentation formalism of GLARE is based on the concept of an
action that can be atomic or composite. Recently, GLARE
was extended with a translation path into the PROMELA
language accepted by the SPIN model checker. The idea of
dividing the SPIN model into several agents is similar to
the use of cooperating TA, where each TA plays a role of
an agent. A GL described in Asbru [14], [21] is called a
plan. The temporal dimension of Asbru is a main advantage
over other languages of this domain since it bridges the gap
between the data delivered from monitoring devices (e.g. blood
tests, manual examination, etc.) and the treatment plan. From
the semantical point of view an Asbru plan is a hierarchical
composition of nondecomposable subplans (actions) stored
in a plan-specification library, which are executed by the
user or by an external call to a computer program. The
formal verification of GLARE and Asbru protocols requires
an additional translation into a formal model. For example, a
translation path first from Asbru to the Karlsruhe Interactive
Verifier (KIV), and further, to the SMV formal model checker
was developed [9]. This makes it difficult to trace back the
results of properties verification and adjust the initial model
if necessary. Moreover, non of the existing formalisms for
GLs modeling provide real-time system analysis and platform
oriented code synthesis tools as opposite to TIMES tool [7].
III. FORMALIZATION APPROACH
The control flow of the electronic devices as well as of the
complementary decision-support system should be based on
the parts of the same GL that act as an intersection point be-
tween medical software and electronic devices. We formalize
a stage of patient medical treatment when the diagnosis has
been already performed. This way some parts of the treatment
protocol can be delegated to an electronic device.
In order to bridge the gap between medical software and
electronic devices we have to make these two worlds speak
the same language. Moreover, the language of the framework
chosen for formal representation should be simple enough
to be understood by someone not familiar with its syntax.
Therefore, a graphical interpretation is a big advantage. We use
TAT as a key formalism for protocols representation [23], since
TIMES tool includes not only a GUI for system modeling
but also a model-checker engine that supports verification
of system properties that are expressed with CTL logic. A
medical GL represented using TAT can be turned into a fully
deterministic model [7] thus enabling further embedded or
decision-support system code synthesis step.
a) Timed Automaton extended with Tasks: Timed Au-
tomaton (TA) [6] is a formal model of computation used to
describe a system behaviour and its progress in time. TA is
an extension of the classical Automaton that is a finite state
graph composed of the finite set of locations Loc and transition
relations (edges) ↪→. TA extends the classical Automaton
with the finite set of clocks C and a set of constraints over
clocks ClockCons(C), where constraints are conjunctions,
disjunctions and negations of atomic expressions over clocks
in the form x ./ n, x ∈ C, n ∈ N0 for ./∈ {<,≤, >,≥,=}.
Each location is characterized by an invariant (I) that specifies
a constraint on a clock under which TA can stay in this location
and/ or enforce a transition to another location. An edge of
TA e = (l, g, a, r, l′) ⊆↪→ represents a transition from l to l′
(l, l′ ⊆ Loc), where g is a guard of e, which indicates when
the transition can be executed, r is the set of clocks that is
reset when the edge is taken, and a is the action of e, a ⊆ Act.
The timed model checker UPPAAL [10], a precursor of
TIMES tool [3], implements TA extended with vac ljreriables.
Similarly to clocks, variables can be used within guards of
edges and location invariants. Upon a transition, variables can
be updated with values of a finite set, which, however, does not
need to be known beforehand, i. e., it can be constructed on-
the-fly upon the state space traversal. A set of cooperating TA
is called a network of TA. The cooperation mechanism may
either make use of shared (global) variables or be realized as
joint execution of dedicated transitions, denoted as rendezvous
synchronization. TAT [7] is an extension of TA with tasks
that represent pieces of code associated with locations of the
model. The execution semantics of TAT is the one of TA
extended with a task queue. Any time the task is triggered
by a transition it is added to the task queue, after which it
will be executed upon a chosen scheduling policy.
b) Modeling with TAT: An example of modeling a step-
by-step medical action with TAT is presented in Section IV-A.
One TAT can describe one instance of a medical GL. A
combination of GLs applied to one patient can be composed
from a set of protocol instances represented with a network
of TAT cooperating with each other. GLs modeling with TAT
is more general than any of the existing GLs representation
formalisms and may create a larger number of design choices.
However, it provides a high flexibility in choosing levels of
abstraction. Various plans of the medical guideline can be
represented with corresponding TAT models. Separate compo-
nents hierarchically embedded in the plan can be represented
either as a network of TAT or tasks of those TAT models. The
synchronization among TATs as well as their parallel execution
is then realized using the cooperation mechanism of TA. The
sequential, cyclical and iterative steps of plans are explicitly
modeled in TAT as a sequence of TAT conditional locations
connected with guarded transition relations.
Each formalized medical protocol should have entry and
exit points. The entry point in TAT is represented by an initial
location and signifies the beginning of treatment procedure.
The exit points are the locations that determine the end of the
treatment that can be classified by positive and negative results.
A positive result would mean that the goal of the treatment
procedure was achieved and thus the treatment can be stopped.
The negative exit point indicates that the treatment has failed
and a change of protocol is required.
Actions, such as observations, medications, procedures,
analytical computations or drug treatment modifications in
TAT-base GL are easily represented as tasks of the model.
The notion of time that performs the mapping of the action
into the time scale is explicitly modeled with clock guards and
invariants of the model. The choice of an action that depends
on some specific conditions may change with time since the
values of the parameters involved in these conditions can be
updated at any transition. Decisions on choosing among all
possible paths in the TAT-based GL models are taken upon
guards of the transition relations.
GLs actions and effects are often not instantaneous. Actions
may have some duration, which can be modeled as the worst-
case execution time of a task; while effects may be delayed,
which we represent as a deadline and levels of treatment
effectiveness (see Section IV-B) TAT introduces the possibility
to mark transitions with probabilities that may represent the
level of evidence or experience with respect to one choice or
another. In other words, the TAT-based approach is expres-
sive enough to represent the step-by-step actions of medical
protocols as well as treatment response definition.
IV. IMATINIB CASE STUDY
Imatinib, marketed by Novartis as Gleevec or Glivec, is a
drug used to treat Chronic Myelogenous Leukemia (CML),
Gastrointestinal Stromal Tumors (GISTs) and a number of
other malignancies. A complete drug administration protocol
of Imatinib can be found here [5]. It includes over 50 pages.
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Figure 1. Drug delivery, measurements and Imatinib dose adjustment models
A. Dose Adjustment and Delivery Models
The dose should be administered once a day (p1 = 1
day). The model is a network of three cooperating TATs. The
first TAT of the network consists of two locations (init1 and
action1) and is responsible for the periodic drug delivery. Thus
every period p1 (t1 == p1), TAT is transitioning to the action1
location. On this transition the clock t1 is reset to 0 and the
GiveDose task is activated (added to the scheduling queue).
The transition from the action1 to the init1 location is then
taken. This model would either give a periodic reminder to a
medical doctor to give a dose to a patient or send a command
to a drug delivery device if this process is fully automated.
The second TAT model composed of two locations represents
a periodic action of performing medical tests, that activates the
task of measuring (measure) the level of neutrophils (N N)
and platelets (N T) every period p4 = 14 days (2 weeks). The
measure task of this model will update the values of N N and
N T variables of the third, Imatinib dose adjustment, model
that is described below. The original model is composed of
the elements with solid lines only.
The recommended dose of Imatinib is 400 mg/day for
patients in the chronic phase (transition (↪→) from Init to
chronic p) of CML and 600 mg/day for patients in the
accelerated phase (Init ↪→ blast accel) of CML. Therefore,
the first two transitions of the model represent the choice of
the treatment according to the patient condition. The dose
may be increased from 400 mg to 600 mg in patients with
the chronic phase of the disease (chronic p ↪→ LoL resp) or
from 600 mg to a maximum of 800 mg given as 400 mg
twice daily (blast accel ↪→ LoL resp and p1 = p2, where p2
= half day) in patients with accelerated phase or blast crisis
in case of: (i) disease progression at any time; (ii) failure to
achieve a satisfactory hematological or cytogenetic response;
or (iii) loss of a previously achieved hematological and/or
cytogenetic response. The complementary TAT model of the
response definition [8] is presented in Section IV-B.
In the chronic phase of CML, marked with a rectangle in
Figure 1, if the level of neutrophils (ANC) goes below 1.0 x
109/l (N N<=n lowerB) and/or level of platelets goes below
50 x 109/l (N T<=t lowerB):
1) Stop Imatinib until ANC >1.5 x 109/l and platelets >75
x 109/l (chronic p ↪→ anemia ch);
2) Resume treatment with Imatinib at previous dose, (ane-
mia ch ↪→ chronic p, N fails accounts to the number
of anemia occurrences);
3) In the event of recurrence of ANC <1.0 x 109/l and/or
platelets <50 x 109/l, repeat step 1 and resume Imatinib
at reduced dose of 300 mg (anemia ch ↪→ repeti-
tive anemia);
The treatment of a patient in the accelerated phase of CML
or in the blast crisis (starting dose 600 mg) is represented in
the lower part of Figure 1.
B. Response Definitions
The response to Imatinib treatment [8] is measured based
on hematological, cytogenetic and molecular tests. The hema-
tological test measures the levels of various White Blood
Cells (WBL). The cytogenetic test measures the value of
Ph+ chromosome mutations, that is a specific chromosomal
abnormality associated with CML. Molecular test measures
the level of a specific BCR-ABL transcripts of the Philadelphia
chromosome. Based on the results of tests performed in
specific time intervals (3, 6, 12 and 18 months) the response
to a treatment can be classified as optimal, suboptimal and
failure.!!! !
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Figure 2. Response definitions to the treatment with Imatinib
Figure 2 lists the definitions of three different levels of
responses in a quantitative way. Even though the three tests
should be evaluated in parallel, hematological response is
expected to be observed first and is classified either as a Com-
plete Hematologic Response (CHR) or as no CHR (NoCHR).
The cytogenetic response has five gradations that are ob-
served in projection to already achieved CHR. Similarly, the
molecular response is evaluated after a Complete Cytogenetic
Response and, consequently, CHR are achieved. Therefore, the
three mentioned types of response can be aggregated into one
accumulated response achievement.
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Figure 3. Response definition graph
Figure 3 depicts a graph with three sets of bars for each
defined time when tests should be performed (3, 6, 12 and18
months). Each set contains three bars. The leftmost bar
corresponds to the minimum level of the optimal response,
while the rightmost represents the maximum level still eval-
uated as failure. The middle (gray) bar is associated with a
suboptimal response. Optimal response means that based on
current knowledge, the patient is projected to have a normal
survival. From the quantitative point of view, if the value
of measured cumulative response achievement is above the
optimal response bar the result will still be evaluated as
optimal. The concept of failure here means that the patient
still may do well also for years, but will never become an
optimal responder, this way, a change of treatment should
be considered. Therefore, if the accumulated response value
is below the rightmost bar it is considered to be a failure.
Suboptimal response is a grey area between failure and optimal
response. The condition of a suboptimal responder is transitory
by nature, so it is not yet clear if a suboptimal responder
would benefit more from an early change of therapy or from
the continuation of the same treatment.
The three cumulative curves γ1, γ2 and γ3 crossing the
graph represent three different scenarios of progressive patient
reaction to the treatment. The first (γ1) curve corresponds
to a situation when an optimal response is achieved. The
second (γ2) curve represents a failure of the treatment after
one year. The third (γ3) curve represents lack of response to
the treatment within 6 month. Based on the response definition
we can build an observer TA that would control the level of
accumulated response achievements. The least restrictive way
would be to build it based on the level of failure bars. This way
we would like to insure that the progressive patient reaction
to the treatment will always remain at least above the failure
level, at the level of suboptimal response and higher.
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Figure 4. Observer TA
The controlling observer TAT is depicted on Figure 4 and
represent a complementary model to the one presented in
Section IV-A. The two models synchronize by means of
a shared variable LoL resp. The periods p1and p2 of the
model are assigned to equal 3 and 6 months respectively. We
have only two periods since time will also be accumulated.
Execution of the model starts from the initial location INIT in
which the model will stay for 3 month after the treatment has
been started. Afterwards it will either transit to the FAILURE
location and thus set the shared Boolean variable LoL resp
to true or, if the response level is at least at the border
level of failure, go to the next location in which it will stay
for another 3 months (6 months in total from the beginning
of treatment). The model may proceed up to the NORMAL
SURVIVAL location. The input data to the model, such as the
amount of Ph+ chromosomes or the ABL level should come
from the measurement TAT similar to the one in Section IV-A.
C. Model Verification and Correction
The verification of a system with UPPAAL or TIMES
requires that the system is closed, which means that the
behavior (transitions from one state to another) of the system is
completely determined by the states of itself. However, some
of the transition guards of the Imatinib protocol and response
observer presented above depend on the information, such as
the values of level of the neutrophils and platelets or counts
of the Ph+ chromosomes coming from external patient body
reaction models. The Module Checking approach [19] suggests
to compose an open system with the maximal environment,
that enables all the external nondeterministic choices, make
the guards that depend on the environment always evaluated
to true. This composition will be a closed system that contains
all possible behaviors of that system combined with any
other environments. Such a composition raises the level of
non-determinism in the model behavior, however, the model
structure remains the same and thus can be verified.
1) Validation of structural properties: The case study above
represents treatment of a chronic disease, which by definition
may not have any positive result. However, there still should
be a positive exit point (location) to describe even a highly
nonprobable case of a miracle. Therefore, we artificially add
this kind of location (stop positive) together with an additional
transitions marked with dashed lines in order to make our exit
location reachable from the chronic p and repetitive anemia.
The locations lack loss resp ch and lack loss resp bl play
the roles of negative exit points. An incompleteness problem
in the dose adjustment protocol exists in both the chronic
and the acceleration phases, where once we go to the repet-
itive anemia or anemia 2 locations there is either no out-
going transition. This problem can be found by verifying
whether the stop positive or lack loss resp ch locations are
always reachable from chronic p location: chronic p–>E<>
(stop positive or lack loss resp ch) and finding the coun-
terexample leading to the repetitive anemia deadlock location.
This way, in the chronic phase part of our case study we add a
transition from the repetitive anemia to the lack loss resp ch
location. Another incompleteness problem was detected in the
response definition model presented in [8]. Its does not say
anything about what will happen after 18 months, therefor
we added, artificially, a self loop to the location for the case
when response stays at the same level and a transition to the
FAILURE location, in case of loss of response.
2) Real-time and Life-cycle Properties Verification: The
verification of the real-time and life-cycle properties should
be performed after the structural protocol verification, when
there are no obvious structural defects. Since potentially an
automatic decision-support system can be combined with an
autonomous electronic device, it is essential to perform the
verification of the real-time properties of the system, so that
communication tokens and, therefore, notifications will never
be delayed more then a deadline. This kind of verification is
called Schedulability Analysis [15] and can be automatically
performed in TIMES tool for the parts of the protocol that are
planned to be automated, e.g. a periodic drug delivery task
combined with some other computational tasks running on the
same computational unit. Life-cycle properties are those that
require that the modeled system contains all the components
of the real system, including the patient model. However, the
patient model is a very complicated task. There exist several
models of the patient body reaction. However, they reflect only
a specific aspect of drug concentration prediction in the blood.
Among them we can name the pharmakokinetical models [13]
and the SVM-based approach [29].
V. CONCLUSIONS
In this paper we have applied a methodology of the area of
embedded systems design to a computer-based interpretation
of medical protocols. The methodologie exploits the Timed
Automata extended with Tasks (TAT) model widely used for
the real-time systems analysis. We have shown that TAT
is expressive enough to represent a step-by-stem treatment
procedures as well as formalize a non immediate effect of
the treatment which is important for closing the patient care
loop. We have presented the Imatinib dose adjustment protocol
case study and a model of the response levels control based
on the levels of accumulated achievements. We where able
to fix some incompleteness problems in these models. The
verification of life-cycle properties of medical GLs required
a patient body reaction model. There exist several models
that may predict the drug concentration in the patient blood,
however, their use with respect to our case study implies the
change of the protocol or use of another protocol, such as the
therapeutic drug monitoring approach [20]. In the next step of
our work we will focused on closing the design loop.
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